Evidence map›Paper›PMID 26702765›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2016

Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study.

Pablo Espinosa, Ruth M Pfeiffer, Zaida García-Casado, Celia Requena, Maria Teresa Landi, Rajiv Kumar, Eduardo Nagore

Open access · greenAbstract read
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. International Dermoscopy Society consensus recommendations for the management of lentigo maligna.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Review
  4. Review
  5. Article
  6. Multiple primary melanomas: Our experience.Experimental and therapeutic medicine · 2021
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Pablo EspinosaDepartment of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
Ruth M PfeifferBiostatistics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, USA.
Zaida García-CasadoLaboratory of Molecular Biology, Instituto Valenciano de Oncología, Valencia, Spain.
Celia RequenaDepartment of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain.
Maria Teresa LandiGenetic Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, USA.
Rajiv KumarMolecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Eduardo NagoreDepartment of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain. Electronic address: eduardo_nagore@ono.com.
Fundación Instituto Valenciano de Oncología · ESNational Cancer Institute · USGerman Cancer Research Center · DE

Funding

Family Studies ZIACP004410 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$56.1M
Methods for Epidemiology StudiesZIACP010181 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBERT, PAUL · 2009 to 2025
$34.8M
Intramural NIH HHS ZIA CP004410
6 · The paper itself

Abstract

backgroundMelanoma survivors are at an increased risk of developing other malignancies, including keratinocyte skin cancer (KSC). While it is known that many risk factors for melanoma also impact risk of KSC in the general population, no previous study has investigated risk factors for KSC development in melanoma patients.

objectiveWe assessed associations of personal and clinical characteristics, including skin phenotype and variations in the melanocortin 1 receptor (MC1R) gene, with KSC risk in melanoma patients. PATIENTS AND

methodsWe used prospective follow-up information on 1200 patients treated for melanoma at the Instituto Valenciano de Oncología, Spain, between 2000 and 2011. We computed hazard ratios and 95% confidence intervals (CIs) for the association of clinical, personal and genetic characteristics with risk of KSC, squamous cell carcinoma (SCC), or basal cell carcinoma (BCC) from Cox proportional hazard models. Five-year cumulative incidence based on competing risk models of SCC, BCC or KSC overall was computed using multivariate subdistribution hazard models. To assess predictive performance of the models, we computed areas under the receiver-operating characteristic curves (AUCs, discriminatory power) using cross-validation.

resultsMedian follow-up was 57.2 months; a KSC was detected in 163 patients (13.6%). In multivariable Cox models, age, sex, sunburns, chronic sun exposure, past personal history of non-melanoma skin cancer or other non-cutaneous neoplasia, and the MC1R variants p.D294H and p.R163Q were significantly associated with KSC risk. A cumulative incidence model including age, sex, personal history of KSC, and of other non-cutaneous neoplasia had an AUC of 0.76 (95% CI: 0.71-0.80). When p.D294H and p.R163Q variants were added to the model, the AUC increased to 0.81 (95% CI: 0.77-0.84) (p-value for difference <0.0001).

conclusionsIn addition to age, sex, skin characteristics, and sun exposure, p.R163Q and p.D294H MC1R variants significantly increased KSC risk among melanoma patients. Our findings may help identify patients who could benefit most from preventive measures.

Indexed as

AdolescentAdultAgedAged, 80 and overBasal Cell CarcinomaCarcinoma, Squamous CellFemaleGenotypeHair ColorHumansKeratinocytesMaleMelanomaMiddle AgedNeoplasms, Second PrimaryNeoplasm StagingReceptor, Melanocortin, Type 1Keratinocyte skin cancerMC1RMelanomaNon-melanoma skin cancerRisk factorsSecond malignancy

Identifiers

PMID26702765
PMCPMC7100359
OpenAlexW2207232411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.